These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 29455596)

  • 41. Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.
    Liaw BC; Shevach J; Oh WK
    Curr Urol Rep; 2015 Mar; 16(3):13. PubMed ID: 25677235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges.
    Somerfield MR; Einhaus K; Hagerty KL; Brouwers MC; Seidenfeld J; Lyman GH;
    J Clin Oncol; 2008 Aug; 26(24):4022-6. PubMed ID: 18711193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of intermittent androgen suppression in biochemically recurrent or newly diagnosed metastatic prostate cancer.
    Crook J
    Curr Opin Support Palliat Care; 2013 Sep; 7(3):258-64. PubMed ID: 23912384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication.
    Qin X; Zhang H; Ye D; Yao X; Zhang S; Dai B
    Andrology; 2013 May; 1(3):512-6. PubMed ID: 23536478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ASCO Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: Guideline Summary.
    J Oncol Pract; 2006 Sep; 2(5):258-261. PubMed ID: 29447032
    [No Abstract]   [Full Text] [Related]  

  • 47. ASCO 2006 Update of the Breast Cancer Follow-Up and Management Guideline in the Adjuvant Setting.
    J Oncol Pract; 2006 Nov; 2(6):317-318. PubMed ID: 29447564
    [No Abstract]   [Full Text] [Related]  

  • 48. 2006 Update of the ASCO Recommendations for Antiemetics in Oncology: Guideline Summary.
    J Oncol Pract; 2006 Jul; 2(4):193-195. PubMed ID: 29452007
    [No Abstract]   [Full Text] [Related]  

  • 49. UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies Summary of changes.
    Kokorovic A; So AI; Serag H; French C; Hamilton RJ; Izard JP; Nayak JG; Pouliot F; Saad F; Shayegan B; Aprikian A; Rendon RA
    Can Urol Assoc J; 2022 Aug; 16(8):243-244. PubMed ID: 35905484
    [No Abstract]   [Full Text] [Related]  

  • 50. ASCO Recommendations on Fertility Preservation in Cancer Patients: Guideline Summary.
    J Oncol Pract; 2006 May; 2(3):143-146. PubMed ID: 29443586
    [No Abstract]   [Full Text] [Related]  

  • 51. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline Summary and Q&A.
    Ligibel JA; Bohlke K; Alfano CM
    JCO Oncol Pract; 2022 Oct; 18(10):695-697. PubMed ID: 35787022
    [No Abstract]   [Full Text] [Related]  

  • 52. Erratum: Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline Summary.
    JCO Oncol Pract; 2022 Nov; 18(11):775-778. PubMed ID: 37053029
    [No Abstract]   [Full Text] [Related]  

  • 53. Prostate Cancer: Summary from ASCO 2015.
    Can Urol Assoc J; 2015; 9(7-8):S162-4. PubMed ID: 26316917
    [No Abstract]   [Full Text] [Related]  

  • 54. Metastatic Renal Cell Cancer: Summary from ASCO 2015.
    Can Urol Assoc J; 2015; 9(7-8):S158-61. PubMed ID: 26316916
    [No Abstract]   [Full Text] [Related]  

  • 55. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update: ASCO Guideline Q and A.
    Virgo KS; Rumble RB; Talcott JA
    JCO Oncol Pract; 2023 Oct; 19(10):843-846. PubMed ID: 37463395
    [No Abstract]   [Full Text] [Related]  

  • 56. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
    Basch EM; Somerfield MR; Beer TM; Carducci MA; Higano CS; Hussain MH; Scher HI;
    J Clin Oncol; 2007 Nov; 25(33):5313-8. PubMed ID: 17925542
    [TBL] [Abstract][Full Text] [Related]  

  • 57. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
    Loblaw DA; Mendelson DS; Talcott JA; Virgo KS; Somerfield MR; Ben-Josef E; Middleton R; Porterfield H; Sharp SA; Smith TJ; Taplin ME; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
    J Clin Oncol; 2004 Jul; 22(14):2927-41. PubMed ID: 15184404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.
    Virgo KS; Rumble RB; Talcott J
    J Clin Oncol; 2023 Jul; 41(20):3652-3656. PubMed ID: 37011338
    [No Abstract]   [Full Text] [Related]  

  • 59. 2007 Update of ASCO Practice Guideline for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: Guideline Summary.
    J Oncol Pract; 2007 May; 3(3):175-177. PubMed ID: 29455596
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.